A Novel Score to Predict Individual Risk for Future Alzheimer’s Disease: A Longitudinal Study of the ADNI Cohort
Journal of Alzheimer’s Disease · 24.09.2024 · 101 (3) · 923-936
DOI: 10.3233/jad-240532 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Alzheimer’s Disease, online erschienen am 03.09.2024. Verfasst von Hongxiu Guo und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. Hauptthemen laut MEDLINE: Alzheimer Disease, Cognitive Dysfunction, Disease Progression. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 44 Literaturangaben.
Themen: Demenz
Abstract (Originalsprache)
Background
Identifying high-risk individuals with mild cognitive impairment (MCI) who are likely to progress to Alzheimer’s disease (AD) is crucial for early intervention.
Objective
This study aimed to develop and validate a novel clinical score for personalized estimation of MCI-to-AD conversion.
Methods
The data from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) study were analyzed. Two-thirds of the MCI patients were randomly assigned to a training cohort ( n = 478), and the remaining one-third formed the validation cohort ( n = 239). Multivariable logistic regression was performed to identify factors associated with MCI-to-AD progression within 4 years. A prediction score was developed based on the regression coefficients derived from the logistic model and tested in the validation cohort.
Results
A lipidomics-signature was obtained that showed a significant association with disease progression. The MCI conversion scoring system (ranged from 0 to 14 points), consisting of the lipidomics-signature and five other significant variables (Apolipoprotein ɛ 4, Rey Auditory Verbal Learning Test immediate and delayed recall, Alzheimer’s Disease Assessment Scale delayed recall test, Functional Activities Questionnaire, and cortical thickness of the AD signature), was constructed. Higher conversion scores were associated with a higher proportion of patients converting to AD. The scoring system demonstrated good discrimination and calibration in both the training cohort (AUC = 0.879, p of Hosmer-Lemeshow test = 0.597) and the validation cohort (AUC = 0.915, p of Hosmer-Lemeshow test = 0.991). The risk classification achieved excellent sensitivity (0.84) and specificity (0.75).
Conclusions
The MCI-to-AD conversion score is a reliable tool for predicting the risk of disease progression in individuals with MCI.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Neurology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
- Department of General Medicine, Binzhou Medical University Hospital, Binzhou, China.
- Department of Pharmacology, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Zitieren
APA
Guo, H., Sun, S., Yang, Y., Ma, R., Wang, C., Zheng, S., Wang, X., Li, G., Alzheimer’s Disease Neuroimaging Initiative, & Alzheimer’s Disease Metabolomics Consortium (2024). A Novel Score to Predict Individual Risk for Future Alzheimer’s Disease: A Longitudinal Study of the ADNI Cohort. Journal of Alzheimer’s Disease, 101(3), 923-936. https://doi.org/10.3233/jad-240532
Vancouver
Guo H, Sun S, Yang Y, Ma R, Wang C, Zheng S, et al. A Novel Score to Predict Individual Risk for Future Alzheimer’s Disease: A Longitudinal Study of the ADNI Cohort. Journal of Alzheimer’s Disease. 2024;101(3):923-936. doi:10.3233/jad-240532
BibTeX
@article{Guo2024,
author = {Guo, Hongxiu and Sun, Shangqi and Yang, Yang and Ma, Rong and Wang, Cailin and Zheng, Siyi and Wang, Xiufeng and Li, Gang and Alzheimer’s Disease Neuroimaging Initiative, Alzheimer’s Disease Neuroimaging Initiative and Alzheimer’s Disease Metabolomics Consortium, Alzheimer’s Disease Metabolomics Consortium},
title = {A Novel Score to Predict Individual Risk for Future Alzheimer’s Disease: A Longitudinal Study of the ADNI Cohort},
journal = {Journal of Alzheimer’s Disease},
year = {2024},
volume = {101},
number = {3},
pages = {923--936},
doi = {10.3233/jad-240532}
}
EUVIMED